Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer Clinical research trials and Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer. Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "T" Clinical Trials Conditions > Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer

Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer



Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer

For Condition: recurrent renal cell cancer,stage 4 renal cell cancer
Status: Recruiting
Sponsor(s): Cornell University Medical College ,
Synopsis: RATIONALE: Tretinoin may help kidney cancer cells develop into normal cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of liposomal tretinoin plus interferon alfa in treating patients who have metastatic kidney cancer.
Details: OBJECTIVES: - Determine the response in patients with metastatic renal cell carcinoma treated with tretinoin liposome and interferon alfa-2b. - Determine the toxicity of this regimen in these patients. - Study retinoic acid receptor expression on tissue obtained from selected patients who have tumor biopsies. OUTLINE: This is a dose-escalation study of tretinoin liposome with concurrent individual dose escalation of interferon alfa-2b. (Phase I closed to accrual as of 9/24/03.) Patients receive tretinoin liposome IV over 30 minutes once weekly and interferon alfa-2b subcutaneously on five consecutive days (M-F) for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tretinoin liposome until the maximum tolerated dose (MTD) has been determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined additional patients are accrued and treated at that dose. (Phase I closed to accrual as of 9/24/03.) During the first 3 weeks of the study, patients receive interferon alfa-2b at weekly dose escalations. After week 3, patients continue at the highest acceptable dose level of interferon alfa-2b for the remainder of the study. (Phase I closed to accrual as of 9/24/03.) Patients are followed at 30 days after the last treatment. PROJECTED ACCRUAL: A total of 3-18 patients will be accrued into the phase I portion of this study (Phase I closed to accrual as of 9/24/03). A total of 14-25 patients will be accrued into the phase II portion of this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed metastatic renal cell carcinoma - Bidimensionally measurable disease - No active brain metastases PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - More than 3 months Hematopoietic: - WBC at least 3,000/mm^3 - Platelet count at least 100,000/mm^3 - No coagulation disorders Hepatic: - Bilirubin less than 1.5 mg/dL - SGOT and SGPT less than 112.5 IU/L each or less than 2.5 times upper limit of normal - No clinically significant hepatic disease, including autoimmune hepatitis Renal: - Creatinine less than 2 mg/dL OR - Creatinine clearance greater than 50 mL/min - No clinically significant renal disease Cardiovascular: - No clinically significant cardiac disease - No thrombophlebitis Pulmonary: - No severe debilitating pulmonary disease - No pulmonary embolism Other: - No history of diabetes mellitus prone to ketoacidosis - No known hypersensitivity to retinoids or retinoic acid derivatives or to interferon or any component of the injection for this study - No thyroid abnormalities that hinder maintaining thyroid function at the normal range - No severe infection - No severe malnutrition - No clinically significant retinal abnormalities - No pre-existing psychiatric condition, especially depression or a history of severe psychiatric disorder - No other concurrent malignancy except nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 effective methods of contraception during and for 1 month after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: - No more than 1 prior biological response modifier therapy or immunotherapy Chemotherapy: - No more than 1 prior chemotherapy regimen Endocrine therapy: - No concurrent steroids Radiotherapy: - At least 4 weeks since prior radiotherapy Surgery: - At least 4 weeks since prior major surgery Other: - No prior retinoid therapy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
DavidNanus,  Study Chair,  Cornell University Medical College

New York Weill Cornell Cancer Center at Cornell University *Recruiting*
New York City,  New York,  10021
United States
Recruiting David  Nanus 212-746-2920

Herbert Irving Comprehensive Cancer Center at Columbia University *Recruiting*
New York City,  New York,  10032
United States
Recruiting Daniel  Petrylak 212-305-1731


Additional Information:
Study ID Numbers:  CDR0000066748;  NYWCCC-0498-209,NCI-V98-1490
Study Start Date: 
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003656

Other Stage 4 Renal Cell Cancer Studies:
1. Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer

2. Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer

3. Allogeneic Stem Cell Transplantation in Treating Patients With Metastatic Renal Cell Cancer

4. Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

5. SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Related Studies:

Other stage 4 renal cell cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials

Tretinoin Plus Interferon alfa in Treating Patients With Metastatic Kidney Cancer
Modify your Search

  Other stage 4 renal cell cancer Clinical Trials
  Other New York Clinical Trials
  Other New York City Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103